Cocrystal Pharma Inc COCP 深 滬
等待開盤 05-22 09:30:00 美东时间
1.13
+0.020
+1.80%
華盛通- 最 高1.145
- 今 開1.11
- 成交量 4.29万股
- 最 低 1.08
- 昨 收 1.11
- 總市值 1557.79万
- 52周最高 2.67
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.8588
- 委 比 70.29%
- 總股本 1378.58万
- 歷史最高 66.00
- 量 比 0.36
- 振 幅 5.86%
- 歷史最低 0.8588
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 26.09 percent increase over losses of $(0.23) per share
05-15 20:09
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma Inc. reported updates on its antiviral pipeline, including the completion of enrollment in the first cohort of its Phase 1b challenge study for CDI-988 as a preventive and treatment for norovirus infection. The company also highlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026 and received FDA Fast Track designation for the drug. Additionally, Cocrystal received an initial $225,000 of an SBIR NIH grant f...
05-15 12:00
Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities
$150,000,000 Cocrystal Pharma, Inc. Common StockPreferred StockWarrantsUnits Cocrystal Pharma, Inc. ("Cocrystal," the "Company," "we," "our," or "us") intends to offer and sell from time to time the
04-24 05:12
Why Cocrystal Pharma Shares Are Cooling Off Monday?
COCP stock is trading lower Monday morning. Learn why Cocrystal Pharma is seeing a pullback after receiving FDA Fast Track designation for CDI-988.
04-06 21:28
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
04-03 01:05
Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection
FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic
04-02 20:04
Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of $(0.32) per share from
03-31 20:14
Cocrystal Pharma Announces First Subjects Dosed In Phase 1b Norovirus Challenge Study To Evaluate CDI-988 As Both Preventive And Treatment For Norovirus Infections
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988No approved treatments or
03-09 20:05
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares Phillip Frost, MD, a Director and 10% Owner, reported the acquisition of common shares of Cocrystal Pharma Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created b
02-10 05:10
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma, Inc. has received IRB approval to initiate a Phase 1b study for CDI-988, an oral antiviral candidate targeting norovirus infections. Enrollment begins Q1 2026, with the study evaluating CDI-988 for both prevention and treatment of norovirus, currently without approved therapies or vaccines. The double-blind, placebo-controlled study at Emory University will involve 40 healthy participants, assessing symptom reduction, viral shed...
2025-12-18 13:00
